Replies to post #9445 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Research report on RA states what many investor already knew:

http://finance.yahoo.com/news/rheumatologists-continue-prefer-enbrel-humira-130000072.html

Rheumatologists Continue to Prefer Enbrel and Humira as Both Their First and Second Line Biologic Agents and the Combined Formulations of Orencia as the Dominant Third Line Agent

Save yourself the money and don’t buy the report!